Payment overview · 2025
General Payments
$1,174.90
36 reported records · 18 companies
Healthcare provider profile · identity verified
Suzanne R Lutton, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SARASOTA, FL · NPI 1013987791
Verified facts
What the public records show
CMS Open Payments records show Suzanne R Lutton, MD received $1,174.90 in general payments during 2025 across 36 reported records.
Abbott Laboratories accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Wegovy.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 753 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 265 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 753 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $466.09 | 39.7% | 10 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $154.14 | 13.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $113.82 | 9.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $59.45 | 5.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.07 | 4.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.84 | 4.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.01 | 3.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.53 | 2.9% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $26.81 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.24 | 2.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.14 | 2.0% | 1 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.94 | 1.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.47 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.12 | 1.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.80 | 1.6% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $18.41 | 1.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $15.68 | 1.3% | 1 | 2025 |
| Spectrum Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.34 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $928.37 | 33 |
| Travel and Lodging | $246.53 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $466.09 | 10 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $154.14 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $113.82 | 4 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $59.45 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $51.07 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.84 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.53 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ROLVEDON Normalized: rolvedon |
Drug | Spectrum Pharmaceuticals Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 753 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
753 | 197 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
265 | 67 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
100 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
753 | 197 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2496 | 722 |
| Atorvastatin Calcium | Atorvastatin Calcium | 764 | 226 |
| Eliquis | Apixaban | 753 | 197 |
| Metoprolol Succinate | Metoprolol Succinate | 737 | 221 |
| Potassium Chloride | Potassium Chloride | 552 | 171 |
| Lisinopril | Lisinopril | 548 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 457 | 141 |
| Sotalol | Sotalol Hcl | 421 | 118 |
| Ezetimibe | Ezetimibe | 420 | 134 |
| Losartan Potassium | Losartan Potassium | 418 | 121 |
| Clopidogrel | Clopidogrel Bisulfate | 353 | 106 |
| Furosemide | Furosemide | 333 | 120 |
| Hydrochlorothiazide | Hydrochlorothiazide | 319 | 94 |
| Spironolactone | Spironolactone | 278 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 268 | 86 |
| Xarelto | Rivaroxaban | 265 | 67 |
| Repatha Sureclick | Evolocumab | 232 | 41 |
| Atenolol | Atenolol | 182 | 53 |
| Carvedilol | Carvedilol | 179 | 49 |
| Valsartan | Valsartan | 140 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 131 | 46 |
| Amiodarone Hcl | Amiodarone Hcl | 117 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 116 | 31 |
| Terazosin Hcl | Terazosin Hcl | 110 | 30 |
| Entresto | Sacubitril/Valsartan | 100 | 27 |
| Flecainide Acetate | Flecainide Acetate | 98 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 27 |
| Simvastatin | Simvastatin | 79 | 25 |
| Digoxin | Digoxin | 76 | 23 |
| Propranolol Hcl Er | Propranolol Hcl | 74 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 22 |
| Warfarin Sodium | Warfarin Sodium | 66 | 17 |
| Propranolol Hcl | Propranolol Hcl | 59 | 22 |
| Klor-Con 10 | Potassium Chloride | 55 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 18 |
| Praluent Pen | Alirocumab | 53 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 52 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 13 |
| Dilt-Xr | Diltiazem Hcl | 47 | 17 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 47 | 17 |
| Farxiga | Dapagliflozin Propanediol | 46 | 14 |
| Fenofibrate | Fenofibrate | 44 | 11 |
| Nitroglycerin | Nitroglycerin | 42 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 13 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Torsemide | Torsemide | 35 | 11 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 11 |
| Brilinta | Ticagrelor | 32 | 11 |
| Eplerenone | Eplerenone | 30 | suppressed |
| Wegovy | Semaglutide | 30 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Verapamil Sr | Verapamil Hcl | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | 12 |
| Matzim La | Diltiazem Hcl | 25 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 25 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Camzyos | Mavacamten | 23 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | 11 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Vyndamax | Tafamidis | 19 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Opsumit | Macitentan | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,174.90 · 36 records | Abbott Laboratories | AVEIR, Barostim Neo System, ELIQUIS, FUROSCIX, JARDIANCE, KEYTRUDA, LEQVIO, LUX-Dx Insertable Cardiac Monitor, LifeVest, MONOFERRIC, NEXLETOL, Nubeqa, REPATHA, ROLVEDON, RYBREVANT, Sotalol Hydrochloride, VYNDAQEL, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error